Business Context and Reporting Period
Maravai LifeSciences Holdings, Inc. filed a Form 8-K reporting events dated August 5, 2021, with the report signed August 10, 2021. The company is an emerging growth company, and its Class A common stock trades on Nasdaq under the symbol MRVI.
Material Transaction
- Maravai and affiliated entities entered into an Agreement and Plan of Merger to sell Vector Laboratories, Inc., the company’s Protein Detection business segment, to Voyager Group Holdings, Inc., an entity affiliated with Thompson Street Capital Partners VI, L.P.
- The agreed purchase price is $124.0 million in cash, subject to customary indemnification obligations and purchase price adjustments.
- Closing was expected in the third quarter of 2021, subject to customary closing conditions.
- The agreement includes customary representations, warranties, covenants, and closing provisions. The filing cautions that these provisions were made solely for the parties and should not be relied upon by investors as statements of fact.
Financial Results and Key Metrics
The filing states that the company issued a press release on August 10, 2021, announcing financial results for the second quarter of 2021. The provided filing text does not include the press release’s revenue, profit, cash flow, margins, debt, liquidity, or other operating metrics.
Guidance, Outlook, Risks, and Unusual Items
- The sale is subject to customary closing conditions and may be affected by purchase price adjustments and indemnification obligations.
- The filing does not provide quantitative guidance or a detailed outlook.
- The divestiture represents a material change to the company’s business portfolio because it removes the Protein Detection segment.
- The filing does not provide the expected accounting gain or loss, tax effects, use of proceeds, or pro forma impact of the transaction.
Important Facts to Verify
- Whether the Vector Laboratories transaction closed in the expected third quarter of 2021 and the final cash consideration received.
- The final purchase price adjustments, indemnification exposure, and any related contingent liabilities.
- The second-quarter 2021 financial metrics and management commentary contained in Exhibit 99.1, which is referenced but not included in the provided text.
- The effect of the divestiture on Maravai’s revenue mix, profitability, cash balance, debt, liquidity, and forward guidance.